Related Experiment Videos
(-)-N,N'-but-2-ene-1,4-diylbimorphinans.
H Schmidhammer1, C F Smith, E Dalkner
1Institute of Organic and Pharmaceutical Chemistry, University of Innsbruck, Austria.
Die Pharmazie
|February 1, 1991
Summary
New bimorphinans were synthesized and tested. Compounds 1 and 3 demonstrated opioid antagonist activity, showing a preference for mu and kappa opioid receptors.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Neuroscience
Background:
- Opioid receptors are critical targets for pain management and addiction therapies.
- Developing novel compounds with specific receptor interactions is essential for improved therapeutic outcomes.
- Bimorphinans represent a class of compounds with potential opioid receptor modulating properties.
Purpose of the Study:
- To synthesize novel N,N'-But-2-ene-1,4-diylbimorphinan compounds.
- To pharmacologically evaluate the synthesized bimorphinans for opioid receptor activity.
- To determine the receptor subtype selectivity (mu and kappa) of active compounds.
Main Methods:
- Chemical synthesis of bimorphinan analogs 1-3.
- Pharmacological assays using mouse vas deferens and guinea pig ileum preparations.
- Assessment of opioid antagonist activity and receptor binding preference.
Main Results:
- N,N'-But-2-ene-1,4-diylbimorphinans 1-3 were successfully synthesized.
- Bimorphinans 1 and 3 exhibited significant opioid antagonist activity.
- Compounds 1 and 3 displayed a preference for mu and kappa opioid receptors.
Conclusions:
- The synthesized N,N'-But-2-ene-1,4-diylbimorphinans, specifically compounds 1 and 3, possess opioid antagonist properties.
- These findings suggest that bimorphinans 1 and 3 interact selectively with mu and kappa opioid receptors.
- This study contributes to the development of novel opioid receptor modulators with potential therapeutic applications.